WESCO International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by WESCO International, Inc. on May 29, 2020. The filing details a significant capital raising event by the Company's wholly owned subsidiary, WESCO Distribution, Inc., intended to finance the previously announced merger with Anixter International Inc.
Key Financial Metrics and Transaction Details
The Company priced a private offering of senior notes with the following terms:
- 5-Year Notes: $1,500 million aggregate principal amount, 7.125% interest rate, due 2025, issued at 100.000% of principal.
- 8-Year Notes: $1,325 million aggregate principal amount, 7.250% interest rate, due 2028, issued at 99.244% of principal.
- Total Proceeds: $2,825 million aggregate principal amount.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as this document focuses on the debt issuance event rather than periodic financial performance.
Material Changes and Use of Proceeds
The aggregate principal amount of the 8-Year Notes was increased from the previously announced $1,000 million to $1,325 million, while the 5-Year Notes were decreased from $1,825 million to $1,500 million. The net proceeds, combined with borrowings under credit facilities and existing cash, will be used to:
- Pay the cash portion of the merger consideration to Anixter stockholders.
- Refinance existing indebtedness of Anixter, including the 5.125% Senior Notes due 2021, and facilitate consent solicitations/tender offers for Anixter's 5.50% Senior Notes due 2023 and 6.00% Senior Notes due 2025.
- Refinance other indebtedness of WESCO.
- Cover fees, costs, and expenses related to the transaction.
Outlook, Risks, and Contingencies
Management highlighted significant risks associated with the proposed merger and the current economic environment. Key contingencies include:
- COVID-19 Impact: Potential material adverse effects on business operations, results, and financial condition due to the health epidemic.
- Regulatory Approval: Risks regarding the timing and terms of required governmental approvals, which could delay or terminate the transaction.
- Integration and Synergies: Risks that the combined company may not achieve anticipated synergies or operate as efficiently as expected.
- Financial Leverage: The risk that the leverage of the combined company may be higher than anticipated.
- Operational Disruption: Potential distraction of management and risks to retaining customers, key personnel, and supplier relationships.
Investor Verification Checklist
- Verify the final closing date and conditions precedent for the WESCO-Anixter merger.
- Review the definitive Merger Agreement to confirm the exact cash consideration per share for Anixter stockholders.
- Monitor the status of regulatory approvals and any potential litigation regarding the transaction.
- Assess the impact of the new debt issuance on the combined company's leverage ratios and interest coverage.
- Examine the specific terms of the consent solicitations and tender offers for Anixter's existing debt.